These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20417358)

  • 1. [Splendours and miseries of the benefit-risk ratio].
    Dupuy A
    Ann Dermatol Venereol; 2010 Apr; 137(4):267-8. PubMed ID: 20417358
    [No Abstract]   [Full Text] [Related]  

  • 2. [A chance we take...].
    Paley-Vincent C
    Ann Dermatol Venereol; 2010 Apr; 137(4):257-9. PubMed ID: 20417355
    [No Abstract]   [Full Text] [Related]  

  • 3. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments.
    Di Lernia V
    Int J Dermatol; 2010 Jun; 49(6):631-5. PubMed ID: 20618466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overseas Drug Safety Information 2008. Risk of infectious diseases associated with the use of immunosuppressive drugs].
    Amanuma K; Morikawa K
    Jpn J Antibiot; 2009 Oct; 62(5):460-70. PubMed ID: 20055123
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.
    Korman BD; Tyler KL; Korman NJ
    Arch Dermatol; 2009 Aug; 145(8):937-42. PubMed ID: 19687432
    [No Abstract]   [Full Text] [Related]  

  • 7. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants.
    Piccinni C; Sacripanti C; Poluzzi E; De Ponti F
    Pharmacoepidemiol Drug Saf; 2013 Apr; 22(4):443-5. PubMed ID: 23554080
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
    Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
    J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIP Raptiva?
    DeFrancesco L
    Nat Biotechnol; 2009 Apr; 27(4):303. PubMed ID: 19352351
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
    Molloy ES; Calabrese LH
    Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibodies in multiple sclerosis].
    Papeix C; Lubetzki C
    Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare neurological condition linked to newer monoclonal antibody biologics.
    Kuehn BM
    JAMA; 2009 Apr; 301(14):1423-4. PubMed ID: 19351930
    [No Abstract]   [Full Text] [Related]  

  • 13. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 14. [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]].
    Luger T; Reusch M; Reich K; Augustin M; Sterry W
    J Dtsch Dermatol Ges; 2009 Apr; 7(4):291-2. PubMed ID: 19500192
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
    Nast A; Augustin M; Boehncke WH; Klaus J; Mrowietz U; Ockenfels HM; Philipp S; Reich K; Rosenbach T; Schlaeger M; Sebastian M; Sterry W; Streit V; Weisenseel P; Rzany B
    J Dtsch Dermatol Ges; 2010 Jan; 8(1):65-6. PubMed ID: 20096063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sense of insecurity.
    Weinberg JM
    Cutis; 2009 Sep; 84(3):126. PubMed ID: 19842569
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of progressive multifocal leukoencephalopathy associated with natalizumab--possibilities and responsibility.
    Holmøy T; Hestvik AL; Vartdal F
    Eur J Neurol; 2006 Aug; 13(8):e2. PubMed ID: 16879280
    [No Abstract]   [Full Text] [Related]  

  • 18. Life threatening liver disease during treatment with monoclonal antibodies.
    Kaiser T; Moessner J; Patel K; McHutchison JG; Tillmann HL
    BMJ; 2009 Feb; 338():b508. PubMed ID: 19224957
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient fatalities potentially associated with efalizumab use.
    Sobell JM; Weinberg JM
    J Drugs Dermatol; 2009 Mar; 8(3):215. PubMed ID: 19271366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.